Aurobindo Pharma announced a significant development today. Its subsidiary, CuraTeQ Biologics, has received a compliance notice from Health...

As global markets prioritise quality and regulatory trust, India’s pharma sector is recalibrating beyond its traditional cost advantage.

The Indian pharma sector made its initial global forays almost a quarter century ago. Companies sought out markets abroad, learnt to deal w...

"The formulation was clinically evaluated in a head-to-head comparative study conducted in India, which established the non-inferiority to ...

Civil society organizations are urging the health ministry to eliminate animal studies in biosimilar development to lower production costs ...

India's drug regulator has released draft guidelines for biosimilar drugs, inviting public comments within 30 days. These revised regulatio...

The Indian government is refining biosimilar drug regulations, aligning with global standards to ensure stringent quality in research and m...

Biocon Biologics has secured USFDA approval to launch the biosimilar of Janssen's Stelara by February 2025, targeting autoimmune conditions...

Following completion of the full set of clinical studies, Dr Reddy's said it will now prepare to file in the US, European Union and other r...

Biocon reported a 64 per cent jump in its net profit for the quarter ending March 2019.

Biosimilar trastuzumab, indicated for breast cancer treatment, has been co-developed by Biocon and Mylan.

The companies in the thick of it are Roche, a $51 billion Swiss pharma major, and Biocon, the Bengaluru-based company led by India’s first ...

Biosimilars are follow-on versions of biologic drugs and far more complex and more difficult to copy than generic drugs because of the stru...

The Indian biogenerics industry is poised to exploit the opportunity they did in the case of generics, although it has no clear advantage a...

Biocon today said it has received approval from the Indian drug regulator to market its biosimilar trastuzumab developed jointly with Mylan.

Biocon said it has received approval to market its biosimilar trastuzumab developed jointly with Mylan for treating breast cancer.

Joining Indian pharma majors who are targeting the $65-billion global biotech drug market.